Featured News Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies January 19, 2023 Read More Shoreline Biosciences Announces Appointment of Cell Therapy Manufacturing Veteran Charles Calderaro III as Chief Technical Officer October 24, 2022 Read More Press Releases Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies January 19, 2023 READ MORE Shoreline Biosciences Announces Oral Presentation on Novel Manufacturing Method of Ink Cells at The 64th American Society of Hematology (ASH) 2022 Meeting December 5, 2022 READ MORE Shoreline Biosciences Announces Appointment of Cell Therapy Manufacturing Veteran Charles Calderaro III as Chief Technical Officer October 24, 2022 READ MORE Shoreline Biosciences to Present Two Posters on Ink Cell Platform At 19th Meeting of The Society for Natural Immunity (NK2022) May 10, 2022 READ MORE Shoreline Biosciences Presents Data at AACR 2022 Demonstrating its Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells April 12, 2022 READ MORE Shoreline Biosciences Announces Oral Presentation on iPSC-Derived NK Cell (iNK) Platform at Innate Killer Summit Meeting 2022 March 28, 2022 READ MORE LOAD MORE Media A Steadying Force in C-Suite: The Changing Role of Biopharma CFOs July 9, 2022 READ MORE BioWorld Insider Podcast: One-on-one with Medical Innovators February 7, 2022 READ MORE BioWorld Insider Podcast: One-on-one with Medical Innovators December 10, 2021 READ MORE Harnessing the body’s natural killers to target cancer December 5, 2021 READ MORE Intelligent Cells: Shoreline Builds Immunotherapy Platform, Pipeline with $140M Financing November 8, 2021 READ MORE California Life Sciences awarded Kite Pharma, a Gilead company, and Shoreline Biosciences the 2021 Strategic Partnership of the Year Award November 4, 2021 READ MORE LOAD MORE
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies January 19, 2023 READ MORE
Shoreline Biosciences Announces Oral Presentation on Novel Manufacturing Method of Ink Cells at The 64th American Society of Hematology (ASH) 2022 Meeting December 5, 2022 READ MORE
Shoreline Biosciences Announces Appointment of Cell Therapy Manufacturing Veteran Charles Calderaro III as Chief Technical Officer October 24, 2022 READ MORE
Shoreline Biosciences to Present Two Posters on Ink Cell Platform At 19th Meeting of The Society for Natural Immunity (NK2022) May 10, 2022 READ MORE
Shoreline Biosciences Presents Data at AACR 2022 Demonstrating its Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells April 12, 2022 READ MORE
Shoreline Biosciences Announces Oral Presentation on iPSC-Derived NK Cell (iNK) Platform at Innate Killer Summit Meeting 2022 March 28, 2022 READ MORE
Intelligent Cells: Shoreline Builds Immunotherapy Platform, Pipeline with $140M Financing November 8, 2021 READ MORE
California Life Sciences awarded Kite Pharma, a Gilead company, and Shoreline Biosciences the 2021 Strategic Partnership of the Year Award November 4, 2021 READ MORE
